Silencing of the TFPI-2 gene associated with hypermethylation of the promoter has recently been described in several cancer cell lines derived from choriocarcinoma (Hube et al, 2003b), glioma (Konduri et al, 2003), fibrosarcoma, breast and prostate cancers (Rao et al, 2003). This evidence concerns the gene TFPI2 and prostate cancer.